Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C

Journal of Clinical Oncology

Volumn 19, Issue 5, 2001, Pages 1485-1492

  Propper, D J ^a   McDonald, A C ^a   Man, A ^a   Thavasu, P ^a   Balkwill, F ^a   Braybrooke, J P ^a   Caponigro, F ^a   Graf, P ^a   Dutreix, C ^a   Blackie, R ^a   Kaye, S B ^a   Ganesan, T S ^a   Talbot, D C ^a   Harris, A L ^a   Twelves, C ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MIDOSTAURIN; MITOMYCIN C; PROTEIN KINASE C INHIBITOR; STAUROSPORINE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG PROTEIN BINDING; ENZYME INHIBITION; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; MALE; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR;

EID: 0035281737     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.5.1485     Document Type: Article

References (32)

1. Signal perception and transduction: The role of protein kinases
2. Linking protein kinase C to cell cycle control
3. Cell cycle phase-specific phosphorylation of human topoisomerase II alpha: Evidence of a role for protein kinase C
4. Regulation of protein kinase C and role in cancer biology
5. Elevated protein kinase C expression in human breast tumor biopsies relative to normal breast tissue
6. Expression pattern of alpha-protein kinase C in human astrocytomas indicates a role in malignant progression
7. Altered protein kinase C activity in biopsies of human colonic adenomas and carcinomas
8. A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo anti-tumor activity
9. Protein-kinase-C: A question of specificity
10. Staurosporine-related compounds, K252a and UCN- 01, inhibit both cPKC and nPKC
11. Activation of protein kinase C subtypes alpha, gamma, delta, epsilon, zeta, and eta by tumor-promoting and nontumor-promoting agents
12. Differential inhibition of the epidermal growth factor-, platelet-derived growth factor-, and protein kinase C-mediated signal transduction pathways by the staurosporine derivative CGP 41251
13. CGP 41251, an inhibitor of VEGF receptor tyrosine kinases
14. Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor
15. Effects of a new protein kinase C inhibitor CGP 41251 on T cell functions: Inhibition of activation, growth, and target cell killing
16. Antitumor activity of the new selective protein kinase C inhibitor 4′-N-benzoyl staurosporine on murine and human tumor models
17. Antitumor effect of CGP41251, a new selective protein kinase C inhibitor, on human non-small cell lung cancer cells
18. Comparison of staurosporine and four analogues: Their effects on growth, rhodamine 123 retention and binding to P-glycoprotein in multidrug-resistant MCF-7/Adr cells
19. The protein kinase C inhibitor CGP 41251, a staurosporine derivative with antitumor activity, reverses multidrug resistance
20. The antitumor activity of doxorubicin against drug-resistant routine carcinoma is enhanced by oral administration of a synthetic staurosporine analogue
21. PKC412A: (CGP 41521)
22. Analytical procedure for the determination of the new antitumour drug N-benzoylstaurosporine and three potential metabolites in human plasma by reversed-phase high-performance liquid chromatography
23. Immunoassay of alpha 1-acid glycoprotein in the Cobas Bio centrifugal analyzer
24. Unpredicted clinical-pharmacology of ucn-01 caused by specific binding to human alpha(1)-acid glycoprotein
25. The protein kinase C inhibitor CGP41251 suppresses cytokine release and extracellular signal-regulated kinase 2 expression in cancer patients
26. Signal transduction pathways mediating astrocyte IL-6 induction by IL-1 beta and tumor necrosis factor-alpha
27. Involvement of protein kinase C and protein tyrosine kinase in lipopolysaccharide-induced TNF-alpha and IL-1 beta production by human monocytes
28. Activation of the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway by conventional, novel, and atypical protein kinase C isotypes
29. 18F-FDG uptake measured by PET as a pharmacodynamic endpoint in anticancer therapy
30. The regulation of protein kinase C by chenodeoxycholate, deoxycholate and several structurally related bile acids
31. 8-chloro-cAMP enhances the growth-inhibitory effect of cytotoxic drugs in human colon-cancer cells
32. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: The importance of sequence of administration